UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2018

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-19871**	**94-3078125**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

25 Recreation Park Drive, Unit 108
Hingham, Massachusetts 02043
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 7.01 Regulation FD Disclosure.

On October 1, 2018, Microbot Medical Inc. (the "Registrant") issued a press release announcing that Harel Gadot, Chief Executive Officer, President and Chairman of the Company, is scheduled to present on Tuesday, October 2, 2018 at 1:30 P.M. (ET) at the Ladenburg Thalmann Healthcare Conference, at the Sofitel Hotel in New York City. A live webcast and subsequent archived replay of the Company's presentation may be accessed via the 'Investors' section, under 'Presentations and Resources' of the Company's website at www.microbotmedical.com. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company is also furnishing presentation materials as Exhibit 99.2 to this Current Report on Form 8-K. The Company is not undertaking to update this presentation.

The information in this Item 7.01 and in Exhibits 99.1 and 99.2 of Item 9.01 is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibits 99.1 and 99.2 of Item 9.01.

Item 9.01 Financial Statements and Exhibits.

Exhibit	Description
99.1	Press Release dated October 1, 2018
99.2	Presentation Materials

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: */s/ HAREL GADOT*
Name: Harel Gadot
Title: President, Chief Executive Officer and Chairman

Date: October 1, 2018

Microbot Medical Inc. to Present at the Ladenburg Thalmann Healthcare Conference

Hingham, MA – October 1, 2018 – Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that Harel Gadot, Chief Executive Officer, President, and Chairman, is scheduled to present at the Ladenburg Thalmann Healthcare Conference on Tuesday, October 2, 2018 at 1:30 pm (ET) at the Sofitel Hotel in New York City.

A live webcast and subsequent archived replay of the Company's presentation may be accessed via the 'Investors' section, under 'Presentations and Resources' of the Company's website at www.microbotmedical.com.

About Microbot Medical, Inc.

Microbot™, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot's current technological platforms platforms, ViRob™, TipCAT™ and CardioSert™, are comprised of three highly advanced technologies, from which the Company is currently developing its first product candidate: the Self Cleaning Shunt, or SCS™, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and focusing on the development of a Multi Generation Pipeline Portfolio (MGPP) utilizing all technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.

The ViRob™ technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time. To learn more about ViRob™ please visit http://www.microbotmedical.com/technology/virob/.

TipCAT™ is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT™, visit http://www.microbotmedical.com/technology/tipcat/.

CardioSert™ technology is a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal surgery. The CardioSert™ technology features unique steering and stiffness control capabilities, and it was originally developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as peripheral intervention, neurosurgery and urology. CardioSert™ was part of a technological incubator supported by the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully completed pre-clinical testing.

Investor Contacts:

Michael Polyviou
EVC Group
mpolyviou@evcgroup.com
732-933-2754

###

microbot medical



FORWARD LOOKING STATEMENTS

THIS DOCUMENT IS PRIVATE AND CONFIDENTIAL, CONTAINS SENSITIVE BUSINESS INFORMATION OF MICROBOT MEDICAL INC. ("MICROBOT") AND IS NOT FOR PUBLIC DISTRIBUTION. This document has been prepared for informational purposes only and is provided personally to you. By accepting this document you agree to keep its contents strictly confidential, not to copy any portion of this document and to return it to Microbot promptly upon its request. This document contains summary information about Microbot, does not purport to be complete, and no representations or warranties about such information are made by Microbot or its representatives.

This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities of Microbot. Any such offer will be made only pursuant to an effective registration statement or an exemption from registration.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission, such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

THE INITIAL SPARK…

EVOLUTION OF SURGERY…

…and the revolution of robotics in healthcare

1980-1990
Freehand
Surgery

1990-2000
Minimally Invasive
Surgery

Today
Robot Assisted
Surgery



Tomorrow
Micro-robotics

MICRO-ROBOTICS APPLICATIONS



Annual review of BioMed, Micro-robots for MIS, 2010

THE MEDICAL ROBOTICS MARKET

MIS Expected to Reach
>$50B Market
by 2019

Expected
>20% CAGR
through 2023

Applies to
Most Surgical
Specialties

Becoming
Smaller, Automated,
and More Precise

THE MEDICAL ROBOTICS MARKET

Medtronic Announces Acquisition of Mazor Robotics.

PR Newswire, September, 2018

TransEnterix Acquires MST Medical Surgery Technologies

Business Wire, September 23 , 2018

Zimmer Biomet Acquires Medtech SA, Joins Surgical Robotics Fray

Med Device Online, July 20, 2016

Globus Medical Announces Acquisition of Robotics Developer KB Medical

Reuters, August 2, 2017

Johnson & Johnson Announces Formation of Verb Surgical Inc., in Collaboration with Verily

PR Newswire, December 10, 2015

microbot medical

TECHNOLOGY PLATFORMS

ViRob

- Autonomous Advancing Micro-Robot (AAMR)
- ViRob demonstrates the ability to advance within cavities similar to the typical human body's lumens





TipCAT

- TipCAT is a disposable, flexible, self-propelled, see & treat endoscope/catheter





CardioSert

- Combination of a guidewire and microcatheter
- Technology features unique steering and stiffness control capabilities



VIROB FIRST PRODUCT

ViRob
Life in motion

- Self Cleaning Shunt (SCS)
- A novel shunt technology for the continuous prevention of shunt blockage in hydrocephalus and NPH patients


microbot

VP SHUNT MARKET OPPORTUNITY

ViRob
Life in motion

- Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain.
- Hydrocephalus occurs in about 1 in every 500 births in the U.S. alone[1,2]
- Over 1,000,000 people in the United States currently live with hydrocephalus[1]
- It is estimated that more than 700,000 Americans have NPH, but less than 20% receive an appropriate diagnosis[1]
  - The problem is often misdiagnosed as Dementia, Alzheimer's, or Parkinson's[2]
- NPH can cause dementia, difficulty in walking and urinary incontinence[2]

1. NIH, National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/hydrocephalus/detail_hydrocephalus.htm
2. National Hydrocephalus Foundation. http://nhfonline.org/facts-about-hydrocephalus.htm

CURRENT SHUNT FAILURE

ViRob
Life in motion



- Approximately 50% of shunts in the pediatric population fail within two years of placement and repeated neurosurgical operations are often required[1]
- Ventricular catheter blockage is by far the most frequent event[2]

1. Hydrocephalus Association. http://www.hydroassoc.org/complications-of-shunt-systems/
2. World Federation of Neurological Societies. http://www.wfns.org/pages/read_the_reviews/97.php?id=5

SELF CLEANING SHUNT (SCS) – LAB STUDY

ViRob
Life in motion

SCS showed the ability to prevent blockage on a shunt opening



ViRob
Life in motion

Hydrocephalus 2014
Bristol
The Sixth Meeting of the International Society for Hydrocephalus and CSF Disorders
ISHCSF

Laboratory Testing of Micro-Robotic Self-Cleaning Shunt

UK Shunt Testing Lab, Cambridge University, UK

CONCLUSIONS:

"Microbot Medical SCS presents low hydrodynamic resistance. The SCS behaves as a standard ventricular catheter and does not change the hydrodynamic performance of adjustable hydrocephalus valves."

SELF CLEANING SHUNT (SCS) – PRE CLINICAL

ViRob
Life in motion

- Wayne State University
  - Goal: Test and finalize the design of the Company's SCS, using Dr. Carolyn Harris' bio-reactor system that mimics human brain tissue dynamics and biology.
  - Result: Supports the SCS's potential as a viable technology for preventing occlusion in shunts used to treat hydrocephalus.

- Washington University
  - Goal: Execute the necessary animal study to determine the safety and effectiveness of the Company's SCS prototype.
  - Result: Met the primary goal to determine the safety of the Company's SCS™ device that aims to prevent obstruction in CSF catheters.

Integration of the feedback received from both studies will be used in the next development phase of the Company's SCS

INITIATION OF PIVOTAL STUDY

- Commenced pivotal study for SCS in September 2018
- Includes a larger sample size compared to the initial study to validate positive outcome of initial study
- Primary and secondary endpoints will seek to validate the safety and efficacy of the SCS that will be activated in both in-vitro (lab) and in-vivo (animal) models.
- Objective is to conclude the follow up studies and publish the data in mid-2019, which keeps us on track for the regulatory submission."


ORGANIZATION & INFRASTRUCTURE TO EXECUTE PLAN
18

ROBUST IP PLATFORM

FAMILY	TITLE	US PATENT/APP NO.	OTHER COUNTRIES
TipCAT	Tip Propelled Device for Motion Through a Passage	US 9,061,118	Granted: EP (DE, FR, GB, IT), CA, JP, IN , CN (3 patents)
		US 9,937,326	
		US 15/936,878	
	Inflatable Chamber Device for Motion Through a Passage	US 9,427,143	Granted: EP (DE, FR, GB, IT)
		US 15/218,025	
	Inflatable Balloon Device and Applications	US 8,430,810	Pending: EP
		US 8,790,246	
	Multi-view Imaging System	US 8,317,688	-
	Semi-Disposable Endoscope	US 8,398,540	Granted: EP (DE, FR, GB)
ViRob	Vibrating Robotic Crawler	US 8,294,333	Granted: IL, IN
			Pending: CN (allowed), EP
	Self Cleaning Shunt	US 9,393,389	Granted: CN, JP, CA
		US 15/187,003 (allowed)	Pending: EP, IN
	Stent for Restenosis Prevention	US 9,510,959	-
	Device for Prevention of Shunt Stenosis	US 9,675,748	Pending: EP (allowed), CA, IL
		US 15/592,227	
CardioSert	Guide Wire for Use with Cardiovascular Lesions	-	Pending: EP, IL
	Guidewire Having Selectively Adjustable Stiffness and Tip Curvature	US 9,586,029	-
	Double Concentric Guidewire	US 15/748,658	Pending: EP, CN, JP, IN, CA, IL

PROVEN LEADERSHIP TEAM

Prof. Moshe Shoham
Member of the Scientific Advisory Board & Co-Founder

Prof. Shoham is a worldwide acclaimed authority in the field of robotics, conducting research in the robotic field for over the past 20 years, with a special focus on kinematics and dynamics of robots, sensor integration, multi-finger hands and medical applications.

- Founder of Mazor Surgical Technologies Ltd. (Nasdaq: MZOR)
- Foreign Member, US National Academy of Engineering
- Head of the robotics lab at Israel's Technion's Faculty of Mechanical Engineering. Formerly the director of the robotic laboratory of the Department of Mechanical Engineering, Columbia University, NY.

Harel Gadot
CEO, President & Chairman

Mr. Gadot was formerly a Worldwide Group Marketing Director at Ethicon Inc., a multi-billion dollar division of Johnson & Johnson company (NYSE: JNJ). Harel was with J&J for a decade between 2000-2010.

- Previously held leadership positions for Ethicon Inc. in Europe, Middle East and Africa.
- Served on the board of directors and led the business development for ConTIPI Ltd., an early stage medical device company, which was acquired by Kimberly Clark Corp (NYSE:KMB) in 2012.

Hezi Himelfarb
GM & COO

Mr. Himelfarb has more than 30 years of management experience in hi-tech and medical device companies.

- Previously served as CEO of IceCure Medical, a TASE publicly traded company. Hezi was responsible for establishing a U.S subsidiary and leading the company's transition from clinical phase to commercial sales.
- Previously was Chief Executive Officer of Remon Medical Technologies Ltd., a developer of smart, miniature implants, which was acquired in 2008 by Boston Scientific Corporation.

PROVEN LEADERSHIP TEAM

David Ben Naim
CFO

Mr. Ben Naim is a CPA licensed in the State of Israel. Prior to joining Microbot Medical, Mr. Ben Naim operated DBN Financial.

- Previously served as CFO of Insuline Medical Ltd, a public company listed on the Tel-Aviv Stock Exchange (TASE:INSL).
- Prior to that Mr. Ben Naim served as CFO of Crow Technologies 1977 Ltd, a public company listed on the OTCQB (CRWTF), from 2008 – 2011.

Ahava Stein
Director, Regulatory Affairs

Ms. Stein, is a regulatory affairs, clinical and QA consultant with over 18 years of experience working directly with the FDA.

- Regulatory experience includes all types of regulatory submissions for a wide variety of innovative medical devices.

Simon Sharon
CTO

Mr. Sharon brings 23 years of R&D and general management in the medical devices space. Prior to Microbot Medical Mr. Sharon managed the R&D at Icecure Medical, an early stage, public medical device company. Mr. Sharon was the General Manger of Anorad Israel, a subsidiary of Rockwell Automation which manufactures sub-micron precision motion systems.

- Holds a B.Sc. from the Technion Institute of Technology and an M.Sc in Mechanical engineering from MIT where he specialized in motion control and Robotics

STRENGTHENED BALANCE SHEET

The sale of STEM assets for **$4 million**

Two separate capital market transactions totaling over **$13.5 million**

Non-dilutive grants in excess of **$735,000** Israel Ministry of Economy; European Commission

MULTIPLE OPPORTUNITIES



INVESTMENT CONSIDERATIONS

- Addressing multi-billion, high growth, underserved markets
- Developing three micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs
- Initial neuro product with comprehensive value propositions poised to be submitted for FDA approval within 24 months
- Potential pipeline designed to deliver additional solutions to other medical conditions every 12-24 months
- Significant IP creates barrier to entry
- Proven leadership team, includes Prof. Moshe Shoham, founder of Mazor Robotics (NASDAQ:MZOR)